BTCY (Biotricity) Short-Term Debt: $25.80 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BTCY Biotricity Inc BTCY
21 GF Score
Price $0.11
GF Value $0.39
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Biotricity Short-Term Debt?

Biotricity BTCY 21 Short-Term Debt is $25.80 Mil as of Mar. 2026. GuruFocus rates BTCY with a GF Score™ of 21/100 and a GF Value™ of $0.39 (Possible Value Trap). The stock has 7 warning signs investors should review.

Biotricity's Short-Term Debt for the quarter that ended in Mar. 2026 was $25.80 Mil.

Biotricity's quarterly Short-Term Debt increased from Sep. 2025 ($12.80 Mil) to Dec. 2025 ($13.55 Mil) and increased from Dec. 2025 ($13.55 Mil) to Mar. 2026 ($25.80 Mil).

Biotricity's annual Short-Term Debt increased from Mar. 2024 ($11.64 Mil) to Mar. 2025 ($12.02 Mil) and increased from Mar. 2025 ($12.02 Mil) to Mar. 2026 ($25.80 Mil).

Biotricity Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Biotricity Short-Term Debt Related Terms

Biotricity Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Biotricity's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotricity Short-Term Debt Chart

Biotricity Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 4.77 11.64 12.02 25.80

Biotricity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.02 12.49 12.80 13.55 25.80
BTCY
21GF Score
Biotricity Inc BTCY
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $25.80 Mil mean?
Biotricity (BTCY) has a Short-Term Debt of $25.80 Mil as of Mar. 2026.
Is Biotricity's Short-Term Debt too high?
Biotricity's current Short-Term Debt is $25.80 Mil. Overall, Biotricity has a GF Score™ of 21/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biotricity's Short-Term Debt compare to FEED and LUDG?
Biotricity's Short-Term Debt of $25.80 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Biotricity's current Short-Term Debt is $25.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotricity stock overvalued right now?
Based on GuruFocus' analysis, Biotricity (BTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $0.39, compared to a current price of $0.11 — trading 71.7% below its estimated fair value. The current Short-Term Debt is $25.80 Mil. Biotricity's overall GF Score™ is 21/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Biotricity (BTCY), the current Short-Term Debt is $25.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biotricity (BTCY) Overvalued in 2026?

Based on GuruFocus' analysis, Biotricity stock appears to be undervalued. The current stock price of $0.11 is trading 71.7% below its estimated GF Value™ of $0.39. GuruFocus considers Biotricity to be Possible Value Trap.

Key valuation signals for BTCY:

  • Short-Term Debt: $25.80 Mil
  • GF Value™: $0.39 vs. price of $0.11 (71.7% below fair value)
  • GF Score™: 21/100 with 7 warning signs

No single metric tells the full story. See the BTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biotricity Business Description

Address 203 Redwood Shores Parkway, Suite 600, Redwood City, CA, USA, 94065
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed; Bioheart, which is a personal heart monitor; Biokit, and Biocare health.
21GF Score

Get the complete analysis for BTCY

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.39
GF Value